cytochrome c cycs  (Proteintech)

Journal: Translational Cancer Research

Article Title: Anti-ovarian cancer effects of forsythiaside A: insights from in vitro and in vivo studies

doi: 10.21037/tcr-2025-980

Figure Lengend Snippet: FSA alters apoptosis protein profiles in SK-OV-3 and OVCAR-3 cells. Expression of BAX, BID, CASP3, CYCS, and BCL2 was determined by Western blot following 48-h treatment with control or FSA. β-actin served as a loading control. (A) Representative Western blot images for BAX, BID, CASP3, CYCS, BCL2, and β-actin in SK-OV-3 cells (NC and FSA). (B) Bar graph analysis of protein expression levels relative to β-actin in SK-OV-3 cells. (C) Representative Western blot images for BAX, BID, CASP3, CYCS, BCL2, and β-actin in OVCAR-3 cells (NC and FSA). (D) Bar graph analysis of protein expression levels relative to β-actin in OVCAR-3 cells. Data represent mean ± standard deviation from three independent experiments (n=3). Statistical significance was determined by Student’s t -test. Statistical significance markers: *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001. FSA, forsythiaside A; NC, negative control.

Article Snippet: Membranes were blocked (Epizyme, Cat. No. PS108, Shanghai, China) for 15 min, then incubated overnight at 4 °C with primary antibodies: BCL2-associated X protein (BAX) (Cat. No. 50599-2-Ig), Caspase-3 (CASP3) (Cat. No. 19677-1-AP), beta-actin (β-actin) (Cat. No. 81115-1-RR), BH3 interacting domain death agonist (BID) (Cat. No. 10988-1-AP), and Cytochrome C (CYCS) (Cat. No. 10993-1-AP) from Proteintech (Wuhan, China), and B-cell lymphoma 2 (BCL2) (Cat. No. bs-0032R; Bioss, Beijing, China).

Techniques: Expressing, Western Blot, Control, Standard Deviation, Negative Control

Journal: Translational Cancer Research

Article Title: Neochlorogenic acid inhibits gastric cancer cell growth through apoptosis and cell cycle arrest

doi: 10.21037/tcr-2025-696

Figure Lengend Snippet: Western blot analysis reveals NCA-mediated modulation of apoptosis-associated proteins in HGC-27 and NUGC-3 cells. Following a 48-hour treatment with control or NCA, the expression of BAX, CASP3, BID, CYCS, and BCL2 was examined by Western blotting. β-actin was used as a loading control. Protein levels were normalized to β-actin and expressed as fold changes relative to the untreated control group. Bar graphs depict the quantification of relative protein levels. Data represent mean ± standard deviation from three independent experiments (n=3). Statistical significance was determined by Student’s t -test. *, P<0.05; **, P<0.01; ***, P<0.001. BAX, BCL2-associated X protein; BCL2, B-cell lymphoma 2; BID, BH3 interacting domain death agonist; CASP3, cysteinyl aspartate specific proteinase 3; CYCS, cytochrome c, somatic; NCA, neochlorogenic acid.

Article Snippet: The membranes were then incubated overnight at 4 °C with primary antibodies for BCL2 (B-cell lymphoma 2) (Cat. No. bs-0032R; Bioss, Beijing, China), BID (BH3 interacting domain death agonist) (Cat. No. 10988-1-AP), CYCS (cytochrome c, somatic) (Cat. No. 10993-1-AP) from Proteintech (Wuhan, China), as well as β-actin (Cat. No. 81115-1-RR, Proteintech, Wuhan, China) and BAX (BCL2-associated X protein) (Cat. No. 50599-2-Ig, Proteintech, Wuhan, China).

Techniques: Western Blot, Control, Expressing, Standard Deviation